webinar
Oct. 27-28, 2025, Boston, MA, USA - Booth 114.
Read More

PSMA-ALB-56

  CAS No.: 2306049-48-7   Cat No.: BADC-01474 4.5  

PSMA-ALB-56 is a PSMA-targeting radioligand consisting of a glutamate-urea PSMA-binding entity and an albumin conjugate.

PSMA-ALB-56

Structure of 2306049-48-7

Quality
Assurance

Worldwide
Delivery

24/7 Customer
Support
Category
ADC Cytotoxin
Molecular Formula
C66H95N11O18
Molecular Weight
1330.52

* For research and manufacturing use only. We do not sell to patients.

Size Price Stock Quantity
-- $-- In stock

Looking for different specifications? Click to request a custom quote!

Capabilities & Facilities

Popular Publications Citing BOC Sciences Products
Synonyms
PSMA-ALB-56
IUPAC Name
(2S)-2-[[(1S)-1-carboxy-5-[[(2S)-2-[[4-[[[(2S)-6-[4-(4-methylphenyl)butanoylamino]-2-[[2-[4,7,10-tris(carboxymethyl)-1,4,7,10-tetrazacyclododec-1-yl]acetyl]amino]hexanoyl]amino]methyl]cyclohexanecarbonyl]amino]-3-naphthalen-2-ylpropanoyl]amino]pentyl]carbamoylamino]pentanedioic acid
Canonical SMILES
CC1=CC=C(C=C1)CCCC(=O)NCCCCC(C(=O)NCC2CCC(CC2)C(=O)NC(CC3=CC4=CC=CC=C4C=C3)C(=O)NCCCCC(C(=O)O)NC(=O)NC(CCC(=O)O)C(=O)O)NC(=O)CN5CCN(CCN(CCN(CC5)CC(=O)O)CC(=O)O)CC(=O)O
InChI
InChI=1S/C66H95N11O18/c1-44-15-17-45(18-16-44)9-8-14-55(78)67-27-6-4-12-51(70-56(79)40-74-29-31-75(41-58(82)83)33-35-77(43-60(86)87)36-34-76(32-30-74)42-59(84)85)62(89)69-39-46-19-23-49(24-20-46)61(88)71-54(38-47-21-22-48-10-2-3-11-50(48)37-47)63(90)68-28-7-5-13-52(64(91)92)72-66(95)73-53(65(93)94)25-26-57(80)81/h2-3,10-11,15-18,21-22,37,46,49,51-54H,4-9,12-14,19-20,23-36,38-43H2,1H3,(H,67,78)(H,68,90)(H,69,89)(H,70,79)(H,71,88)(H,80,81)(H,82,83)(H,84,85)(H,86,87)(H,91,92)(H,93,94)(H2,72,73,95)/t46?,49?,51-,52-,53-,54-/m0/s1
InChIKey
QIWYPMRCMDYQBF-OWCMGUGRSA-N

PSMA-ALB-56 is a small-molecule drug conjugate (SMDC) designed as a targeted cytotoxin for use in oncology applications. It functions as an ADC-like payload by selectively binding to the prostate-specific membrane antigen (PSMA) expressed on tumor cell surfaces. Upon internalization, PSMA-ALB-56 delivers its cytotoxic component directly to tumor cells, inducing cell cycle arrest and apoptosis through DNA damage and microtubule disruption, depending on its linked payload chemistry.

In conjugate design, PSMA-ALB-56 is linked to albumin or other carrier scaffolds via cleavable linker systems, ensuring systemic stability while enabling intracellular release in PSMA-expressing cells. The linker chemistry controls payload activation, maintaining inactivity during circulation and triggering release upon lysosomal or enzymatic processing. This targeted delivery mechanism enhances specificity to PSMA-positive tumors while limiting off-target effects.

Applications of PSMA-ALB-56 include preclinical and clinical evaluation for prostate cancer therapy and other PSMA-expressing malignancies. Its chemical structure supports diverse linker configurations and controlled intracellular payload release. PSMA-ALB-56 demonstrates defined pharmacokinetic profiles, selective internalization, and consistent cytotoxic activity in PSMA-positive cell lines, providing a mechanistically precise tool for the development of next-generation tumor-targeted conjugates.

What is PSMA-ALB-56?

PSMA-ALB-56 is a cytotoxic agent designed for conjugation in ADCs targeting prostate-specific membrane antigen (PSMA). It combines high potency with selectivity, enabling targeted preclinical research in prostate cancer models and ADC development.

29/9/2017

Dear BOC Sciences, how does PSMA-ALB-56 function in ADCs?

When conjugated to PSMA-targeting antibodies, PSMA-ALB-56 selectively enters tumor cells expressing PSMA. It induces DNA damage or inhibits essential cellular pathways, causing apoptosis and enabling evaluation of tumor-selective cytotoxicity.

10/7/2018

Dear team, what are the main applications of PSMA-ALB-56 in research?

PSMA-ALB-56 is used in preclinical ADC studies to assess payload potency, optimize linker chemistry, and evaluate tumor-selective delivery, facilitating development of prostate cancer-specific ADCs.

14/4/2019

May I ask what chemical features define PSMA-ALB-56?

PSMA-ALB-56 is a small molecule cytotoxin with functional groups enabling stable conjugation to antibodies. Its design supports selective delivery to PSMA-expressing cells while maintaining cytotoxic activity.

12/4/2020

Dear BOC Sciences, could you please advise how PSMA-ALB-56 should be handled safely?

PSMA-ALB-56 is a potent cytotoxin requiring strict lab safety, including PPE, fume hoods, and controlled waste disposal, to prevent accidental exposure during ADC synthesis and testing.

1/5/2019

— Dr. Jason Carter, Senior Scientist (USA)

PSMA-ALB-56 from BOC Sciences arrived with excellent purity, supporting our ADC research.

14/4/2019

— Dr. Kevin Scott, ADC Researcher (USA)

PSMA-ALB-56 was an excellent choice for our targeted conjugation studies. The product quality was consistent and dependable.

1/5/2019

— Ms. Elena Rossi, Molecular Scientist (Italy)

We found the PSMA-ALB-56 supplied by BOC Sciences to be highly reproducible across multiple assay types.

12/4/2020

— Mr. François Dupont, CMC Manager (France)

BOC Sciences provided PSMA-ALB-56 with complete documentation, which supported our regulatory submissions smoothly.

29/9/2017

— Dr. Mark Peterson, Biopharma Scientist (UK)

The turnaround time for PSMA-ALB-56 was fast, enabling us to stay on track with a demanding project schedule.

— Dr. Julia Weber, Oncology Research Scientist (Germany)

Our conjugation trials with PSMA-ALB-56 were successful due to its high stability and well-validated composition.

10/7/2018

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

The dilution calculator equation

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Related Products

Contact our experts today for pricing and comprehensive details on our ADC offerings.

You May Also Be Interested In

From cytotoxin synthesis to linker design, discover our specialized services that complement your ADC projects.

ADC Payload Development Biological Payload Chemical Payload Protein Toxin Nanocarrier Microtubule Inhibitors DNA Damaging Agents RNA Polymerase Inhibitors Protein Degraders

Unlock Deeper ADC Insights

Learn more about payload design, linker strategies, and integrated CDMO support through our curated ADC content.

Maytansine and Its Analogues Cytotoxic Agents Used in Antibody–Drug Conjugates Exatecan Mesylate in ADCs: A New Topo I Inhibitor What is Calicheamicin? What is Monomethyl Auristatin E (MMAE)? What is Monomethyl Auristatin F (MMAF)? What is Pyrrolobenzodiazepine (PBD)? Antiviral Potential of Thapsigargin in COVID-19 Research ADC Payloads Explained: Current Types and Cutting-Edge Research Progress Tubulin Inhibitors - Highly Potential ADC Payloads

Explore More ADC Products

Find exactly what your project needs from our expanded range of ADCs, offering flexible options to fit your timelines and goals.

ADC Cytotoxin

Powerful Targeted Cancer Solutions

ADC  Cytotoxin with Linker

Enhanced Stability And Efficacy

ADC Linker

Precise Conjugation For Success

Antibody-Drug  Conjugates (ADCs)

Maximized Therapeutic Performance

Auristatins

Next-Level Tubulin Inhibition

Calicheamicins

High-Impact DNA Targeting

Camptothecins

Advanced Topoisomerase Inhibition

Daunorubicins / Doxorubicins

Trusted Anthracycline Payloads

Duocarmycins

Potent DNA Alkylation Agents

Maytansinoids

Superior Microtubule Disruption

Pyrrolobenzodiazepines

Ultra-Potent DNA Crosslinkers

Traditional Cytotoxic Agents

Proven Chemotherapy Solutions

Cleavable Linker

Precise Intracellular Drug Release

Non-Cleavable Linker

Exceptional Long-Term Stability

Historical Records: SPB
Send Inquiry
Verification code
Inquiry Basket